Publications by authors named "Ira Gantz"

Claim this Profile
C
Clinical Trial: A Phase 2b Study to Evaluate the Efficacy and Safety of MK-3655 in Individuals With Pre-Cirrhotic MASH.
Annaswamy Raji, Ira Gantz, Michael Crutchlow, Heather Flynn, Lianzhe Xu

Aliment Pharmacol Ther· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Heart failure outcomes captured by adverse event reporting in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the VERTIS CV trial.
Ambarish Pandey, Ahmed A Kolkailah, Darren K McGuire, Robert C Frederich, Nilo B Cater, Ira Gantz

Eur J Heart Fail· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term weight loss and cardiorenal outcomes by baseline BMI in the VERTIS CV trial.
Francesco Cosentino, Samuel Dagogo-Jack, Robert Frederich, Christopher P Cannon, David Z I Cherney, Ira Gantz

Diabetes Obes Metab· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular and Renal Outcomes with Ertugliflozin by Baseline Use of Renin-Angiotensin-Aldosterone System Inhibitors or Diuretics, Including Mineralocorticoid Receptor Antagonist: Analyses from the VERTIS CV Trial.
David Z I Cherney, Robert Frederich, Richard E Pratley, Francesco Cosentino, Samuel Dagogo-Jack, Ira Gantz

Kidney Dis (Basel)· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Ertugliflozin and hospitalization for heart failure across the spectrum of pre-trial ejection fraction: post-hoc analyses of the VERTIS CV trial.
Ambarish Pandey, Ahmed A Kolkailah, Francesco Cosentino, Christopher P Cannon, Robert C Frederich, Ira Gantz

Eur Heart J· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Ertugliflozin Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients With Type 2 Diabetes: Analyses From VERTIS CV.
Samuel Dagogo-Jack, Robert Frederich, Jie Liu, Christopher P Cannon, Harry Shi, Ira Gantz

J Clin Endocrinol Metab· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose-lowering agent: An analysis from VERTIS CV.
Samuel Dagogo-Jack, Christopher P Cannon, David Z I Cherney, Francesco Cosentino, Jie Liu, Ira Gantz

Diabetes Obes Metab· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial.
Samuel Dagogo-Jack, Richard E Pratley, David Z I Cherney, Darren K McGuire, Francesco Cosentino, Ira Gantz

BMJ Open Diabetes Res Care· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus and established cardiovascular disease using insulin: A VERTIS CV substudy.
Ildiko Lingvay, Michelle Greenberg, Silvina Gallo, Harry Shi, Jie Liu, Ira Gantz

Diabetes Obes Metab· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, placebo-controlled study to evaluate the efficacy and safety of adding omarigliptin to insulin therapy in Japanese patients with type 2 diabetes and inadequate glycaemic control.
Takashi Kadowaki, Yutaka Seino, Kohei Kaku, Taro Okamoto, Miho Kameya, Ira Gantz

Diabetes Obes Metab· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Ertugliflozin in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea: A Sub-Study of VERTIS CV.
Matthew J Budoff, Timothy M E Davis, Alexandra G Palmer, Robert Frederich, David E Lawrence, Ira Gantz

Diabetes Ther· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Ertugliflozin in Patients With Diabetes Mellitus Inadequately Controlled by Sulfonylurea Monotherapy: a Substudy of VERTIS CV.
Krzysztof Strojek, A Shekhar Pandey, Vanessa Dell, Melanie Sisson, Shuai Wang, Ira Gantz

Diabetes Ther· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis.
Darren K McGuire, Weichung J Shih, Francesco Cosentino, Bernard Charbonnel, David Z I Cherney, Ira Gantz

JAMA Cardiol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of ertugliflozin in older patients with type 2 diabetes: A pooled analysis of phase III studies.
Richard Pratley, Samuel Dagogo-Jack, Bernard Charbonnel, Shrita Patel, Anne Hickman, Ira Gantz

Diabetes Obes Metab· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial.
Francesco Cosentino, Christopher P Cannon, David Z I Cherney, Urszula Masiukiewicz, Richard Pratley, Ira Gantz

Circulation· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.
Christopher P Cannon, Richard Pratley, Samuel Dagogo-Jack, James Mancuso, Susan Huyck, Ira Gantz

N Engl J Med· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of ertugliflozin across racial groups in patients with type 2 diabetes mellitus.
Jie Liu, Lisa Tarasenko, Annpey Pong, Susan Huyck, Larry Wu, Ira Gantz

Curr Med Res Opin· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of ertugliflozin in Hispanic/Latino patients with type 2 diabetes mellitus.
Jie Liu, Lisa Tarasenko, Annpey Pong, Susan Huyck, Shrita Patel, Ira Gantz

Curr Med Res Opin· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials.
David Z I Cherney, Hiddo J L Heerspink, Robert Frederich, Mario Maldonado, Jie Liu, Ira Gantz

Diabetologia· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Seven Phase 3 Randomized Controlled Trials.
Shrita Patel, Anne Hickman, Robert Frederich, Susan Johnson, Susan Huyck, Ira Gantz

Diabetes Ther· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of ertugliflozin in East/Southeast Asian patients with type 2 diabetes mellitus.
Jie Liu, Shrita Patel, Nilo B Cater, Larry Wu, Susan Huyck, Ira Gantz

Diabetes Obes Metab· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors associated with the discontinuation of dipeptidyl peptidase-4 inhibitors (DPP-4is) after initiation of insulin.
Gail Fernandes, Joana E Matos, Dena H Jaffe, Grace Beyer, Lingfeng Yang, Ira Gantz

Curr Med Res Opin· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SGLT2 Inhibitors and the Risk of Hospitalization for Fournier's Gangrene: A Nested Case-Control Study.
Tongtong Wang, Shrita M Patel, Anne Hickman, Xinyue Liu, Philip LStJ Jones, Ira Gantz

Diabetes Ther· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study.
Ronan Roussel, Santiago Duran-García, Yilong Zhang, Suneri Shah, Carolyn Darmiento, Ira Gantz

Diabetes Obes Metab· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin.
Seung-Hwan Lee, Ira Gantz, Elizabeth Round, Melanie Latham, Edward A O'Neill

BMC Endocr Disord· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis